Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease

被引:159
作者
Soares, Holly D. [1 ]
Potter, William Z.
Pickering, Eve [2 ]
Kuhn, Max [2 ]
Immermann, Frederick W. [5 ]
Shera, David M. [6 ]
Ferm, Mats [8 ]
Dean, Robert A. [9 ]
Simon, Adam J. [10 ]
Swenson, Frank [2 ]
Siuciak, Judith A.
Kaplow, June [7 ]
Thambisetty, Madhav [3 ]
Zagouras, Panayiotis [2 ]
Koroshetz, Walter J. [4 ]
Wan, Hong I. [13 ]
Trojanowski, John Q. [11 ,12 ]
Shaw, Leslie M. [11 ,12 ]
机构
[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[2] Pfizer Worldwide Res & Dev, Groton, CT USA
[3] NIA, Lab Behav Neurosci, Clin Res Branch, Intramural Res Program, Baltimore, MD 21224 USA
[4] NINDS, Div Extramural Res, Bethesda, MD 20892 USA
[5] Pfizer Worldwide Res & Dev, Pearl River, NY USA
[6] Merck Res Labs, Whitehouse Stn, NJ USA
[7] Eisai Med Res, Woodcliff Lake, NJ USA
[8] AstraZeneca Res & Dev, Cent Nervous Syst & Pain Innovat Med, Sodertalje, Sweden
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] AJ Simon Enterprises LLC, Yardley, England
[11] Univ Penn, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[12] Univ Penn, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA
[13] Pfizer Worldwide Res & Dev, Biotherapeut Clin Programs, San Francisco, CA USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
MILD COGNITIVE IMPAIRMENT; DIAGNOSTIC GUIDELINES; NATRIURETIC PEPTIDE; NATIONAL INSTITUTE; RECOMMENDATIONS; WORKGROUPS; DEMENTIA; CORTISOL; BLOOD; APOE;
D O I
10.1001/archneurol.2012.1070
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment. Objective: To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Design: Cohort study. Setting: The Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. Participants: Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects. Main Outcome Measures: Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype. Results: Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B-type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo epsilon 3/epsilon 4 or epsilon 4/epsilon 4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia. Conclusions: Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.
引用
收藏
页码:1310 / 1317
页数:8
相关论文
共 38 条
[1]   The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].
Albert, Marilyn S. ;
DeKosky, Steven T. ;
Dickson, Dennis ;
Dubois, Bruno ;
Feldman, Howard H. ;
Fox, Nick C. ;
Gamst, Anthony ;
Holtzman, David M. ;
Jagust, William J. ;
Petersen, Ronald C. ;
Snyder, Peter J. ;
Carrillo, Maria C. ;
Thies, Bill ;
Phelps, Creighton H. .
ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279
[2]   Alzheimer's Association Report 2011 Alzheimer's disease facts and figures [J].
Thies W. ;
Bleiler L. .
ALZHEIMERS & DEMENTIA, 2011, 7 (02) :208-244
[3]   Regulation of human eotaxin-3/CCL26 expression: Modulation by cytokines and glucocorticoids [J].
Banwell, ME ;
Tolley, NS ;
Williams, TJ ;
Mitchell, TJ .
CYTOKINE, 2002, 17 (06) :317-323
[4]   A Gene Expression Pattern in Blood for the Early Detection of Alzheimer's Disease [J].
Booij, Birgitte Boonstra ;
Lindahl, Torbjorn ;
Wetterberg, Peter ;
Skaane, Nina Voss ;
Saebo, Solve ;
Feten, Guri ;
Rye, Phil D. ;
Kristiansen, Lena Iren ;
Hagen, Nina ;
Jensen, Marianne ;
Bardsen, Ken ;
Winblad, Bengt ;
Sharma, Praveen ;
Lonneborg, Anders .
JOURNAL OF ALZHEIMERS DISEASE, 2011, 23 (01) :109-119
[5]   Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants [J].
Bruno, Davide ;
Nierenberg, Jay J. ;
Ritchie, James C. ;
Lutz, Michael W. ;
Pomara, Nunzio .
PSYCHONEUROENDOCRINOLOGY, 2012, 37 (03) :366-371
[6]   Prediction of Alzheimer's Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide: A Retrospective Analysis of 134 Patients With Mild Cognitive Impairment [J].
Buerger, Katharina ;
Uspenskaya, Olga ;
Hartmann, Oliver ;
Hansson, Oskar ;
Minthon, Lennart ;
Blennow, Kaj ;
Moeller, Hans-Juergen ;
Teipel, Stefan J. ;
Ernst, Andrea ;
Bergmann, Andreas ;
Hampel, Harald .
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (04) :556-563
[7]  
Craig-Schapiro R, 2011, PLOS ONE, V6
[8]   Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia [J].
Csernansky, John G. ;
Dong, Hongxin ;
Fagan, Anne M. ;
Wang, Lei ;
Xiong, Chengjie ;
Holtzman, David M. ;
Morris, John C. .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (12) :2164-2169
[9]   Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide [J].
degliUberti, EC ;
Bondanelli, M ;
Margutti, A ;
Ambrosio, MR ;
Valentini, A ;
Campo, M ;
Franceschetti, P ;
Zatelli, MC ;
Pansini, R ;
Trasforini, G .
NEUROENDOCRINOLOGY, 1996, 64 (05) :398-404
[10]   Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].
Dubois, Bruno ;
Feldman, Howard H. ;
Jacova, Claudia ;
Dekosky, Steven T. ;
Barberger-Gateau, Pascale ;
Cummings, Jeffrey ;
Delocourte, Andre ;
Galasko, Douglas ;
Gauthier, Serge ;
Jicha, Gregory ;
Meguro, Kenichi ;
O'Brien, John ;
Pasquier, Florence ;
Robert, Philippe ;
Rossor, Martin ;
Solloway, Steven ;
Stern, Yaakov ;
Visser, Pieter J. ;
Scheltens, Philip .
LANCET NEUROLOGY, 2007, 6 (08) :734-746